By his own estimate, an AI scribe gives one urologist about two hours of his day back, and an evidence tool built into it has taught him something new in the clinic almost every day. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes back Dr. David Canes, urologist at Lahey Hospital & Medical Center and founder of WellPrept, to talk about how ... Show More
Nov 5
Ep. 341 Understanding Overactive Bladder in Male Patients with Dr. Bilal Chughtai
How many prostate medications and procedures should a man try before anyone checks his bladder? Dr. Bilal Chughtai has met men who worked through an alpha blocker, add-on medications, a minimally invasive prostate procedure, and even resective surgery before anyone named overacti ... Show More
40m 42s
Nov 3
Ep. 340 Understanding Intermediate-Risk Bladder Cancer with Dr. Wesley Yip
By one estimate, half or more of all non-muscle invasive bladder cancer (NMIBC) is intermediate risk, yet the major guidelines still do not define it the same way, which leaves urologists sorting a large, mixed group of patients without a shared playbook for when to resect again, ... Show More
43m 42s
Oct 27
Ep. 338 From Numbers to Decisions: Clinical Utility of Biomarkers in Prostate Cancer Diagnosis with Dr. Amir Lebastchi
Every prostate cancer biomarker returns a number, but the real question is whether that number changes what you do next for the patient. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes Dr. Amir Lebastchi, urologic oncologist at Keck Medicine of USC, to discuss h ... Show More
48m 34s
Feb 2024
Key Advances in Prostate, Kidney, and Bladder Cancers at GU24
<p>Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influen ... Show More
30m 6s
Dec 2023
UROONCO RCC take home message for 2023
<p>In this podcast, UROONCO RCC board members, chief editor Dr. Carmen Mir (ES), and associate editors Dr. Riccardo Bertolo (IT) and Dr. Teele Kuusk (GB), discuss the progress made in the field of kidney cancer during 2023, and what is anticipated for 2024.<br/><br/>Some topics d ... Show More
18m 27s
Oct 2022
Dr Thomas Seisen talks about treatment options for metastatic UTUC
<p>During this episode, Dr. Thomas Seisen (FR), an associate member on the EAU Guidelines Panel for Non-Muscle Invasive Bladder Cancer, answers questions about metastatic upper urothelial cancer (UTUC) treatment options in the 2022 guidelines:</p><ul><li>What are the systemic tr ... Show More
17m 11s
